major insurance changes are coming to glp 1 drugs Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss Designing fiscally viable coverage of

Cell (1995) 81:64150

With newer GLP-1based therapies now emerging, the field has an opportunity to test whether different drugs in this class have distinct effects on aging biology and to identify which patients may benefit most. Larger clinical trials are needed to confirm the findings, determine how long treatment effects last, and establish optimal dosing and treatment duration for both people with HIV and the broader population

It does not establish efficacy

By utilizing a sustained-release formulation, it overcomes the historical challenges of oral bioavailability, providing a steady, reliable defense against the relentless oxidative stress that characterizes post-viral syndromes

To help combat this, add a Glutathione supplement